BioRestorative Therapies(DE:9OF0)
€0.130.00 (0.00%)
DE:9OF0
BioRestorative Therapies financials statements
€0.13
At close:0.00 (0.00%)
BioRestorative Therapies (9OF0) Ratios
1 Followers
BioRestorative Therapies Ratios
DE:9OF0's free cash flow for Q1 2026 was $-3.81M. For the 2026 fiscal year, DE:9OF0's free cash flow was increased by $0.00 and operating cash flow was $-3.81M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.84 | 2.97 | 4.37 | 2.53 | 59.01 |
| Quick Ratio | 0.84 | 2.97 | 4.37 | 2.53 | 59.01 |
| Cash Ratio | 0.41 | 0.15 | 0.34 | 0.29 | 57.79 |
| Solvency Ratio | -3.77 | -2.35 | -3.93 | -2.13 | -51.62 |
| Operating Cash Flow Ratio | -2.90 | -2.20 | -2.47 | -0.99 | -9.15 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -39.62 | 0.00 | -56.47 |
| Net Current Asset Value | $ -586.03K | $ 7.40M | $ 8.78M | $ 8.98M | $ 20.61M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.01 | 0.02 | 0.03 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.02 | 0.03 | 0.03 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.02 | 0.03 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Financial Leverage Ratio | 11.44 | 1.44 | 1.26 | 1.60 | 1.04 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -92.24 | 0.00 | -13.99 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -14.49 |
| Debt to Market Cap | 0.00 | 0.00 | 0.02 | 0.00 | 0.05 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.04 | 0.08 | 2.09 |
| Net Debt to EBITDA | 0.11 | 0.06 | 0.05 | 0.08 | 0.78 |
| Profitability Margins | |||||
| Gross Profit Margin | 93.37% | 93.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -3959.40% | -2239.25% | -10382.33% | -15745.83% | -57191.03% |
| EBITDA Margin | -3901.03% | -2192.10% | -10268.66% | -15645.21% | -56997.32% |
| Operating Profit Margin | -4350.05% | -2881.59% | -10439.49% | -15838.08% | -57191.03% |
| Pretax Profit Margin | -3959.40% | -2239.25% | -7145.20% | -11036.97% | -96311.51% |
| Net Profit Margin | -3959.40% | -2239.25% | -7145.20% | -11036.97% | -96311.51% |
| Continuous Operations Profit Margin | -3959.40% | -2239.25% | -7145.20% | -11036.97% | -96311.51% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 91.02% | 77.71% | 68.44% | 69.69% | 168.40% |
| Return on Assets (ROA) | -349.10% | -73.12% | -82.60% | -80.45% | -197.31% |
| Return on Equity (ROE) | -3992.21% | -105.25% | -104.13% | -128.49% | -205.14% |
| Return on Capital Employed (ROCE) | -4386.10% | -135.44% | -152.14% | -181.52% | -119.10% |
| Return on Invested Capital (ROIC) | -4386.10% | -135.44% | -149.71% | -179.14% | -118.14% |
| Return on Tangible Assets | -401.70% | -77.04% | -87.56% | -84.59% | -202.63% |
| Earnings Yield | -134.21% | -80.88% | -141.95% | -132.90% | -859.46% |
| Efficiency Ratios | |||||
| Receivables Turnover | 23.21 | 2.13 | 7.55 | 7.49 | 9.20 |
| Payables Turnover | 0.02 | 0.06 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 1.00 | 1.10 | 0.29 | 0.24 | 0.12 |
| Asset Turnover | 0.09 | 0.03 | 0.01 | 0.01 | 0.00 |
| Working Capital Turnover Ratio | 0.11 | 0.05 | 0.02 | 0.01 | 0.00 |
| Cash Conversion Cycle | -20519.65 | -6109.53 | 48.32 | 48.75 | 39.67 |
| Days of Sales Outstanding | 15.73 | 171.49 | 48.32 | 48.75 | 39.67 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 20535.38 | 6281.01 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 15.73 | 171.49 | 48.32 | 48.75 | 39.67 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -23.99 | -1.06 | -1.52 | -1.63 | -2.80 |
| Free Cash Flow Per Share | -24.25 | -1.07 | -1.57 | -1.76 | -2.83 |
| Dividend Paid and CapEx Coverage Ratio | -92.95 | -77.51 | -37.59 | -13.43 | -108.61 |
| Capital Expenditure Coverage Ratio | -92.95 | -77.51 | -37.59 | -13.43 | -108.61 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | -39.62 | -19.60 | -4.96 |
| Operating Cash Flow to Sales Ratio | -29.99 | -20.52 | -44.10 | -49.36 | -72.39 |
| Free Cash Flow Yield | -102.76% | -75.09% | -89.95% | -63.86% | -65.19% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.75 | -1.24 | -0.70 | -0.75 | -0.12 |
| Price-to-Sales (P/S) Ratio | 29.50 | 27.69 | 50.33 | 83.05 | 112.06 |
| Price-to-Book (P/B) Ratio | 29.75 | 1.30 | 0.73 | 0.97 | 0.24 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.97 | -1.33 | -1.11 | -1.57 | -1.53 |
| Price-to-Operating Cash Flow Ratio | -0.98 | -1.35 | -1.14 | -1.68 | -1.55 |
| Price-to-Earnings Growth (PEG) Ratio | -0.02 | 0.02 | 0.02 | 0.01 | -0.00 |
| Enterprise Value Multiple | -0.65 | -1.20 | -0.44 | -0.46 | 0.58 |
| Enterprise Value | 9.10M | 10.55M | 6.62M | 8.54M | -15.20M |
| EV to EBITDA | -0.65 | -1.20 | -0.44 | -0.46 | 0.58 |
| EV to Sales | 25.30 | 26.32 | 45.38 | 71.26 | -330.46 |
| EV to Free Cash Flow | -0.83 | -1.27 | -1.00 | -1.34 | 4.52 |
| EV to Operating Cash Flow | -0.84 | -1.28 | -1.03 | -1.44 | 4.57 |
| Tangible Book Value Per Share | -0.39 | 1.02 | 2.20 | 2.62 | 17.69 |
| Shareholders’ Equity Per Share | 0.79 | 1.10 | 2.37 | 2.84 | 18.18 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.80 | 0.05 | 0.03 | 0.03 | 0.04 |
| Net Income Per Share | -31.67 | -1.16 | -2.47 | -3.65 | -37.30 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.69 | 0.70 | 1.68 |
| Research & Development to Revenue | 28.06 | 13.34 | 27.67 | 29.33 | 15.85 |
| SG&A to Revenue | 16.37 | 16.41 | 77.72 | 130.05 | 553.62 |
| Stock-Based Compensation to Revenue | 9.25 | 7.01 | 53.38 | 105.28 | 502.37 |
| Income Quality | 0.76 | 0.92 | 0.62 | 0.45 | 0.08 |
Currency in USD
